{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:38:49Z","timestamp":1793335129974,"version":"4.5.0"},"reference-count":49,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background and Methods: We analyzed trends in overall survival after acute myeloid leukemia (AML) using US registry data covering the years 1975 to 2021. Our study utilized unique patient data from the Surveillance, Epidemiology, and End Results Program (SEER), with 37,615 adult patients included. We employed Kaplan\u2013Meier estimates and competing risk analyses to assess overall survival and risks of AML-related death and death from other causes. Results: Our findings indicate a clear and continuous trend of improved survival in AML patients, attributed to decreased AML-related mortality. Patients aged 60 or younger showed continuous improvement over the entire period, while those aged 61 or older demonstrated improvement starting in the early 2000s. Only patients receiving chemotherapy treatment benefited from ongoing research. No sex-specific differences were found. Subgroup analyses revealed age-dependent differences in survival improvement. The delayed onset of improvement in older patients may be due to the availability of hypomethylating agents and increased access to hematological stem cell transplantation. Conclusion: Our analysis showed, on a high level of abstraction, how ongoing research and availability of new treatment options improved survival for AML patients. Furthermore, subgroup analyses revealed age-dependent differences in this respect. While the data did not allow us to conduct in-depth analyses of treatment regimens, we hypothesized that the later onset of a pattern of improvement in older patients was due to the availability of hypomethylating substances and increased availability of hematological stem cells transplantation for elderly patients.<\/jats:p>","DOI":"10.3390\/cancers17233735","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:47:22Z","timestamp":1763984842000},"page":"3735","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterizing Overall Survival of Patients with Acute Myeloid Leukemia: A Competing Risk Analysis of SEER Data Covering 46 Years"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-9419","authenticated-orcid":false,"given":"Dennis","family":"G\u00f6rlich","sequence":"first","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8956-9541","authenticated-orcid":false,"given":"Leonas","family":"Lanwer","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of M\u00fcnster, 48149 M\u00fcnster, Germany"},{"name":"Faculty 3 Mathematics and Computer Science, University of Bremen, 28359 Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-8218","authenticated-orcid":false,"given":"Cristina","family":"Sauerland","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5777-1420","authenticated-orcid":false,"given":"Utz","family":"Krug","sequence":"additional","affiliation":[{"name":"DKMS Collection Center, 50670 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2674-8098","authenticated-orcid":false,"given":"Andreas","family":"Faldum","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of M\u00fcnster, 48149 M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood.2022016293","article-title":"Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","article-title":"An Overview of Targeted Therapies in Acute Myeloid Leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"Hemasphere"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/COC.0000000000001169","article-title":"Meta-analysis of Therapeutic Approaches in Acute Myeloid Leukemia: Unveiling Trends and Predictors of Treatment Response","volume":"48","author":"Qureshi","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_7","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3324\/haematol.12304","article-title":"Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century","volume":"93","author":"Pulte","year":"2008","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.2012.063602","article-title":"Recent trends in survival of adult patients with acute leukemia: Overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups","volume":"98","author":"Pulte","year":"2013","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115231","DOI":"10.1016\/j.ejca.2025.115231","article-title":"Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study","volume":"220","author":"Vener","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12672-024-01498-9","article-title":"Development and validation of a risk predictive nomogram for colon cancer-specific mortality: A competing risk model based on the SEER database","volume":"15","author":"Li","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zheng, S., Xie, S., Yu, H., Duan, X., He, Y., Ho, C., Wan, Y., Hang, T., Chen, W., and Lyu, J. (2023). Competing-risks analysis for evaluating the prognosis of patients with microinvasive cutaneous squamous cell carcinoma based on the SEER database. BMC Med. Res. Methodol., 23.","DOI":"10.1186\/s12874-023-02109-x"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1186\/s40001-025-03255-2","article-title":"Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database-based study","volume":"30","author":"Luo","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20406207241290886","DOI":"10.1177\/20406207241290886","article-title":"Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients","volume":"15","author":"Tang","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_17","unstructured":"G\u00f6rlich, D., Lanwer, L., Sauerland, C., and Faldum, A. (2025, January 16\u201319). Characterizing overall survival in AML patients: A competing risk analysis of SEER data covering 46 years. Proceedings of the International Symposium ACUTE LEUKEMIAS XIX (ISALXIX), Munich, Germany."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-Estimation from Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/bimj.201800274","article-title":"On the relation between the cause-specific hazard and the subdistribution rate for competing risks data: The Fine-Gray model revisited","volume":"62","author":"Putter","year":"2020","journal-title":"Biom. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the Analysis of Survival Data in the Presence of Competing Risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","article-title":"Competing risks analyses: Objectives and approaches","volume":"35","author":"Wolbers","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10428194.2020.1832662","article-title":"Treatment decision-making in acute myeloid leukemia: A qualitative study of older adults and community oncologists","volume":"62","author":"Loh","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40487-023-00229-4","article-title":"Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial","volume":"11","author":"Genc","year":"2023","journal-title":"Oncol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11912-020-00987-8","article-title":"Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions","volume":"22","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/fon-2022-0565","article-title":"Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database","volume":"19","author":"Dharmani","year":"2023","journal-title":"Future Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/EDBK_239097","article-title":"More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate","volume":"39","author":"Klepin","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: A population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s00432-021-03756-7","article-title":"Patterns of undertreatment among patients with acute myeloid leukemia (AML): Considerations for patients eligible for non-intensive chemotherapy (NIC)","volume":"147","author":"Hubscher","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: A phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s11912-024-01604-8","article-title":"AML in the Elderly\u2013When less may be more","volume":"26","author":"Winer","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/stcltm\/szac015","article-title":"Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia","volume":"11","author":"Servais","year":"2022","journal-title":"Stem. Cells Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1158\/1078-0432.CCR-23-3673","article-title":"Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study","volume":"30","author":"Bazarbachi","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/bloodadvances.2021004435","article-title":"In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: A FILO study","volume":"6","author":"Devillier","year":"2022","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_47","first-page":"1027","article-title":"How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?","volume":"15","author":"Merrill","year":"2004","journal-title":"Cancer Causes Control."},{"key":"ref_48","first-page":"1117","article-title":"How generalizable are the SEER registries to the cancer populations of the USA?","volume":"27","author":"Kuo","year":"2016","journal-title":"Cancer Causes Control."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lu, S.C., Song, W., Pfob, A., and Gibbons, C. (2025). Assessing the representativeness of large medical data using population stability index. BMC Med. Res. Methodol., 25.","DOI":"10.1186\/s12874-025-02474-9"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:01:39Z","timestamp":1763985699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":49,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233735"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233735","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]}}}